Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients

In this study, we examined the association between the pharmacokinetics (PK) level of sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in terms of adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). The PK of sunitinib (SU and DSU) w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Numakura, Kazuyuki, Fujiyama, Nobuhiro, Takahashi, Makoto, Igarashi, Ryoma, Tsuruta, Hiroshi, Maeno, Atsushi, Huang, Mingguo, Saito, Mitsuru, Narita, Shintaro, Inoue, Takamitsu, Satoh, Shigeru, Tsuchiya, Norihiko, Niioka, Takenori, Miura, Masatomo, Habuchi, Tomonori
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5982748/
https://ncbi.nlm.nih.gov/pubmed/29861870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25423
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares